Structure-activity relationships of the antimalarial agent artemisinin. 8. Design, synthesis, and CoMFA studies toward the development of artemisinin-based drugs against leishmaniasis and malaria

Journal of Medicinal Chemistry

Volumn 46, Issue 20, 2003, Pages 4244-4258

  Avery, Mitchell A ^a,b   Muraleedharan, Kannoth M ^a   Desai, Prashant V ^a   Bandyopadhyaya, Achintya K ^a   Furtado, Marise M ^a   Tekwani, Babu L ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 DEOXYARTEMISININ; ARTEMISININ; ARTEMISININ DERIVATIVE; ARTEMISITENE; LACTONE; OCTAHYDRO 3,6ALPHA DIMETHYL 3,12 EPOXY 9ALPHA (3' PHENYLPROPYL) 12H PYRANO[4,3 J] 1,2 BENZODIOXEPIN 10(3H) ONE; OCTAHYDRO 3,6ALPHA DIMETHYL 3,12 EPOXY 9ALPHA [3' (4 N,N DIMETHYLAMINOPHENYL)PROPYL] 12H PYRANO[4,3 J] 1,2 BENZODIOXEPIN 10(3H) ONE; OCTAHYDRO 3,6ALPHA DIMETHYL 3,12 EPOXY 9ALPHA [3' [3,5 BIS(TRIFLUOROMETHYL)PHENYL]PROPYL] 12H PYRANO[4,3 J] 1,2 BENZODIOXEPIN 10(3H) ONE; OCTAHYDRO 3,6ALPHA DIMETHYL 3,12 EPOXY 9BETA (2' CYANOETHYL) 12H PYRANO[4,3 J] 1,2 BENZODIOXEPIN 10(3H) ONE; OCTAHYDRO 3,6ALPHA DIMETHYL 3,12 EPOXY 9BETA [3' (4 METHANESULFONYLPHENYL)PROPYL] 12H PYRANO[4,3 J] 1,2 BENZODIOXEPIN 10(3H) ONE; OCTAHYDRO 3,6ALPHA DIMETHYL 3,12 EPOXY 9BETA [3' (4 METHYLTHIOPHENYL)PROPYL] 12H PYRANO[4,3 J] 1,2 BENZODIOXEPIN 10(3H) ONE; OCTAHYDRO 3,6ALPHA DIMETHYL 3,12 EPOXY 9BETA [3' (4 N,N DIMETHYLAMINOPHENYL)PROPYL] 12H PYRANO[4,3 J] 1,2 BENZODIOXEPIN 10(3H) ONE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANTIMALARIAL ACTIVITY; ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; DRUG DESIGN; DRUG SYNTHESIS; LEISHMANIA DONOVANI; LEISHMANIASIS; MALARIA; NONHUMAN; PROMASTIGOTE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIMALARIALS; ANTIPROTOZOAL AGENTS; ARTEMISININS; CLONE CELLS; DRUG DESIGN; ELECTROSTATICS; INHIBITORY CONCENTRATION 50; L-LACTATE DEHYDROGENASE; LEISHMANIA DONOVANI; MALARIA, FALCIPARUM; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PLASMODIUM FALCIPARUM; SESQUITERPENES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0141680852     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030181q     Document Type: Article

References (75)

1. Cumming, J. N.; Ploypradith, P.; Posner, G. H. Antimalarial activity of artemisinin (qinghaosu) and related trioxanes: Mechanism(s) of Action. Adv. Pharmacol. (San Diego) 1997, 37, 253-297.
2. Avery, M. A.; Alvim-Gaston, M.; Woolfrey, J. R. Synthesis and structure-activity relationships of peroxidic antimalarials based on artemisinin. Adv. Med. Chem. 1999, 4, 125-217.
3. Klayman, D. L. Qinghaosu (artemisinin): An antimalarial drug from China. Science 1985, 228, 1049-1055.
4. Robert, A.; Dechy-Cabaret, O.; Cazelles, J.; Meunier, B. From mechanistic studies on artemisinin derivatives to new modular antimalarial drugs. Acc. Chem. Res. 2002, 35, 167-174.
5. Wu, Y. How might qinghaosu (artemisinin) and related compounds kill the intraerythrocytic malaria parasite? A chemist's view. Acc. Chem. Res. 2002, 35, 255-259.
6. Cazelles, J.; Robert, A.; Meunier, B. Alkylating capacity and reaction products of antimalarial trioxanes after activation by a heme model. J. Org. Chem. 2002, 67, 609-619.
7. Wang, D.-Y.; Wu, Y.-L. A possible antimalarial action mode of qinghaosu (artemisinin) series compounds. Alkylation of reduced glutathione by C-centered primary radicals produced from antimalarial compound qinghaosu and 12-(2,4-dimethoxyphenyl)-12-deoxoqinghaosu. J. Chem. Soc. Chem. Commun. 2000, 22, 2193-2194.
8. Pandey A. V.; Tekwani, B. L.; Sing, R. L.; Chauhan, V. S. Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite. J. Biol. Chem. 1999, 274, 19383-19388.
9. Wu, W.-M.; Wu, Y.; Wu, Y.-L.; Yao Z.-J.; Zhou, C.-M.; Li, Y.; Shan, F. Unified mechanistic framework for the Fe(II)-induced cleavage of qinghaosu and derivatives/analogues. The first spin-trapping evidence for the previously postulated secondary C-4 radical. J. Am. Chem. Soc. 1998, 120, 3316-3325.
10. Paitayatat, S.; Tarmchompoo, B.; Thebtatranonth, Y.; Yuthavong, Y. Correlation of antimalarial activity of artemisinin derivatives with binding affinity with ferroprotoporphyrin IX. J. Med. Chem. 1997, 40, 633-638.
11. Haynes, R. K.; Vonwiller, S. C. From qinghao, marvelous herb of antiquity, to the antimalarial trioxane qinghaosu-Some remarkable new chemistry. Acc. Chem. Res. 1997, 30, 73-79.
12. (a) Meshnick, S. R.; Yang, Y. Z.; Lima, V.; Cuypers, F.; Kamchonwongpaisan, S.; Yuthavong, Y. Iron-dependent free radical generation from the antimalarial agent artemisinin (qinghaosu). Antimicrob. Agents Chemother. 1993, 37, 1108-1114.
13. (b) Haynes, R. K.; Hung-On, P. H.; Voerste, A. Ring opening of artemisinin (qinghaosu) and dihydroartemisinin and interception of the open hydroperoxides with formation of N-oxides-A chemical model for antimalarial action. Tetrahedron Lett. 1999, 40, 4715-4718.
14. Bhisutthibhan, J.; Pan, X. Q.; Hossler, P. A.; Walker, D. J. The Plasmodium falciparum translationally controlled tumor protein homologue and its reaction with the antimalarial drug artemisinin. J. Biol. Chem. 1998, 273, 16192-16198.
15. Olliaro, P. L.; Haynes, R. K.; Meunier, B.; Yuthavong, Y. Possible modes of action of the artemisinin-type compounds. Trends Parasitol. 2001, 17, 122-126.
16. Grellepois, F.; Chorki, F.; Crousse, B.; Ourevitch, M.; Bonnet-Delpon, D.; Jean-Pierre, B. Anhydrodihydroartemisinin and its 10-trifluoromethyl analogue: Access to novel D-ring-contracted artemisinin trifluoromethyl ketones. J. Org. Chem. 2002, 67, 1253-1260.
17. Jung, M.; Lee, K.; Kendrick, H.; Robinson, B. L.; Croft, S. L. Synthesis, stability, and antimalarial activity of new hydrolytically stable and water-soluble (+)-Deoxoartelinic acid. J. Med. Chem. 2002, 45, 4940-4944.
18. Posner, G. H.; Jeon, H. B.; Ploypradith, P.; Paik, I. H.; Borstnik, K.; Xie, S.; Shapiro, T. A. Orally active, water-soluble antimalarial 3-Aryltrioxanes: Short synthesis and preclinical efficacy testing in rodents. J. Med. Chem. 2002, 45, 3824-3828.
19. Hindley, S.; Ward, S. A.; Storr, R. C.; Searle, N. L.; Bray, P. G.; Park, B. K.; Davies, J.; O'Neill, P. M. Mechanism-based design of parasite-targeted artemisinin derivatives: Synthesis and antimalarial activity of new diamine containing analogues. J. Med. Chem. 2002, 45, 1052-1063.
20. Chorki, F.; Grellepois, F.; Crousse, B.; Hoang, V. D.; Hung, N. V.; Bonnet-Delpon, D.; Begue, J. P. First synthesis of 10α -(trifluoromethyl)deoxoartemisinin. Org. Lett. 2002, 4, 757-759.
21. Liao, X.-B.; Han, J.-Y.; Li, Y. Michael addition of artemisitene. Tetrahedron Lett. 2001, 42, 2843-2845.
22. Chorki, F.; Grellepois, F.; Crousse, B.; Ourevitch, M.; Bonnet-Delpon, D.; Begue, J. P. Fluoro artemisinins: Difluoromethylene ketones. J. Org. Chem. 2001, 66, 7858-7863.
23. (a) Han, J.; Lee, J. G.; Min, S. S.; Park, S. H.; Angerhofer, C. K.; Cordell, G. A.; Kim, S. U. Synthesis of new artemisinin analogues from artemisinic acid modified at C-3 and C-13 and their antimalarial activity. J. Nat. Prod. 2001, 64, 1201-1205.
24. (b) Ekthawatchai, S.; Kamchonwongpaisan, S.; Kongsaeree, P.; Tarnchompoo, B.; Thebtaranonth, Y.; Yuthavong, Y. C-16 artemisinin derivatives and their antimalarial and cytotoxic activities: Syntheses of artemisinin monomers, dimers, trimers, and tetramers by nucleophilic additions to artemisitene. J. Med. Chem. 2001, 44, 4688-4695.
25. Denis, M. B.; Davis, T. M. E.; Hewitt, S.; Incardona, S.; Nimol, K.; Fandeur, T.; Poravuth, Y.; Lim, C.; Socheat, D. Efficacy and safety of Dihydroartemisinin-Piperaquine (Artekin) in Cambodian children and Adults with uncomplicated Falciparum malaria. Clin. Infect. Dis. 2002, 35, 1469-1476, and references therein.
26. (a) Brossi, A.; Venugopalan, B.; Dominguez Gerpe, L.; Yeh, H. J. C.; Flippen-Anderson, J. L.; Buchs, P.; Luo, X. D.; Milhous, W.; Peters, W. Arteether, a new antimalarial drug: Synthesis and antimalarial properties. J. Med. Chem. 1988, 31, 645-650.
27. (b) Brewer, T. G.; Grate, S. J.; Peggins, J. O.; Weina, P. J.; Petras, J. M.; Levine, B. S.; Heiffer, M. H.; Schuster, B. G. Fatal neurotoxicity of arteether and artemether. Am. J. Trop. Med. Hyg. 1994, 51, 251-259.
28. (c) Brewer, T. G.; Peggins, J. O.; Grate, S. J.; Petras, J. M.; Levine, B. S.; Weina, P. J.; Swearengen, J.; Heiffer, M. H.; Schuster, B. G. Neurotoxicity in animals due to arteether and artemether. Trans. R. Soc. Trop. Med. Hyg. 1994, 88, 33-36.
29. (d) Lee, I. S.; Hufford, C. D. Metabolism of antimalarial sesquiterpene lactones. Pharm., Ther. 1990, 48, 345-355.
30. Singh, N. P.; Lai, H. Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci. 2001, 70, 49-56.
31. Thomas, E.; Heather, D.; Axel, S.; Hayato, M.; Chitambar, C. R. The anti-malarial artesunate is also active against cancer. Int. J. Oncol. 2001, 18, 767-773.
32. Li, Y.; Shan, F.; Wu, J.-M.; Wu, G.-S.; Ding, J.; Xiao, D.; Yang, W.-Y.; Atassi, G.; Leonce, S.; Caignard, D.-H.; Renard, P. Novel antitumor artemisinin derivatives targeting G1 phase of the cell cycle. Bioorg. Med. Chem. Lett. 2001, 11, 5-8.
33. Posner, G. H.; Ploypradith, P.; Parker, M. H.; O'Dowd, H.; Woo, S.-H.; Northrop, J.; Krasavin, M.; Dolan, P.; Kensler, T. W.; Xie, S.; Shapiro, T. A. Antimalarial, antiproliferative, and antitumor activities of artemisinin-derived, chemically robust, trioxane dimers. J. Med. Chem. 1999, 42, 4275-4280.
34. Beekman, A. C.; Wierenga, P. K.; Woerdenbag, H. J.; Van Uden, W.; Pras, N.; Konings, A. W. T.; El-Feraly, F. S.; Galal, A. M.; Wikstroem, H. V. Artemisinin-derived sesquiterpene lactones as potential antitumour compounds: Cytotoxic action against bone marrow and tumour cells. Planta Med. 1998, 64, 615-619.
35. Jung, M. Synthesis and cytotoxicity of novel artemisinin analogues. Bioorg. Med. Chem. Lett. 1997, 7, 1091-1094.
36. Liu, C. H.; Zou, W. X.; Lu, H.; Tan, R. X. Antifungal activity of Artemisia annua endophyte cultures against phytopathogenic fungi. J. Biotechnol. 2001, 88, 277-282.
37. Vikas, D.; Rao, P. S.; Lakshmi, N. M. Antimicrobial activity of artemisinin and its precursors. Curr. Sci. 2000, 78, 709-713.
38. Yang, D. M.; Liew, F. Y. Effects of qinghaosu (artemisinin) and its derivatives on experimental cutaneous leishmaniasis. Parasitology 1993, 106, 7-11.
39. Kern, P. Leishmaniasis. Antibiot. Chemother. 1981, 30, 203-223.
40. De Carvalho, P. B.; Arribas, M. A. D. G.; Ferreira, E. I. Leishmaniasis: What do we know about its chemotherapy? Rev. Bras. Cienc. Farm. 2000, 36, 69-96.
41. Loiseau, P. M.; Bories, C. Recent strategies for the chemotherapy of visceral leishmaniasis. Curr. Opin. Infect. Dis. 1999, 12, 559-564.
42. Selzer, P. M.; Pingel, S.; Hsieh, I.; Ugele, B.; Chan, V. J.; Engel, J. C.; Bogyo, M.; Russell, D. G.; Sakanari, J. A.; McKerrow, J. H. Cysteine protease inhibitors as chemotherapy: Lessons from a parasite target. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 11015-11022.
43. Moreno, J.; Canavate, C.; Chamizo, C.; Laguna, F.; Alvar, J. HIV-Leishmania infantum co-infection: Humoral and cellular immune responses to the parasite after chemotherapy. Trans R. Soc. Trop. Med. Hyg. 2000, 94, 328-332.
44. Kennedy, M. L.; Cortes-Selva, F.; Perez-Victoria, J. M.; Jimenez, I. A.; Gonzalez, A. G.; Munoz, O. M.; Gamarro, F.; Castanys, S.; Ravelo, A. G. Chemosensitization of a multidrug-resistant Leishmania tropica line by new sesquiterpenes from Maytenus magellanica and Maytenus chubutensis. J. Med. Chem. 2001, 44, 4668-4676.
45. Berman, J. D.; Grog, I. M. Leishmania mexicana: Chemistry and biochemistry of sodium stibogluconate (Pentostam). Exp. Parasitol. 1988, 67, 96-103.
46. Brost, P.; Ouellette, M. New mechanisms of drug resistance in parasitic protozoa. Annu. Rev. Microbiol. 1995, 49, 427-460.
47. Olliaro, P. L.; Bryceson, A. D. M. Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol. Today 1993, 9, 323-328.
48. Thakur, C. P. Comparison of glucose versus fat emulsion in the preparation of amphotericin B for use in kala-azar. Trans R. Soc. Trop. Med. Hyg. 1994, 88, 689-699.
49. Dietz, R.; Fagundes, S. M. S.; Brito, E. F.; Milan, E. P.; Fietosa, T. F.; Suassuna, F. A. B.; Fonschiffrey, G.; Ksionski, G.; Dember, J. Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days. Trans R. Soc. Trop. Med. Hyg. 1995, 89, 309-311.
50. (a) Vroman, J. A.; Alvim-Gaston, M.; Avery, M. A. Current progress in the chemistry, medicinal chemistry and drug design of artemisinin based antimalarials. Curr. Pharm. Design 1999, 5, 101-138.
51. (b) Vroman, J. A.; Elsohly, H. N.; Avery, M. A. Conjugate addition of a cyano-Gilman cuprate to an acrylic acid: Homologation of artemisinic acid and subsequent conversion to 16-butylartemisinin. Synth. Commun. 1998, 28, 1555-1562.
52. (c) Avery, M. A.; Mehrotra, S.; Bonk, J. D.; Vroman, J. A.; Goins, D. K. ; Miller, R. Structure-activity relationships of the antimalarial agent artemisinin. 4. Effect of substitution at C-3. J. Med. Chem. 1996, 39, 2900-2906.
53. (d) Avery, M. A.; Alvim-Gaston, M.; Rodrigues, C. R.; Barreiro, E. J.; Cohen, F. E.; Sabnis, Y. A.; Woolfrey, J. R. Structure-activity relationships of the antimalarial agent artemisinin. 6. The development of predictive in vitro potency models using CoMFA and HQSAR methodologies. J. Med. Chem. 2002, 45, 292-303.
54. (a) Avery, M. A.; Alvim-Gaston, M.; Vroman, J. A.; Wu, B.; Ager, A.; Peters, W.; Robinson, B. L.; Charman, W. Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates. J. Med. Chem. 2002, 45, 4321-4335.
55. (b) Avery, M. A.; Gao, F.; Chong, W. K. M.; Mehrotra, Sanjiv; Milhous, W. K., Structure-activity relationships of the antimalarial agent artemisinin. 1. Synthesis and comparative molecular field analysis of C-9 analogues of artemisinin and 10-deoxoartemisinin. J. Med. Chem. 1993, 36, 26, 4264-75.
56. (c) Avery, M. A.; Mehrotra, S.; Theresa, L. J.; Bonk, J. D.; Vroman, J. A.; Miller R. Structure-activity relationships of the antimalarial agent artemisinin. 5. Analogues of 10-deoxoartemisinin substituted at C-3 and C-9. J. Med. Chem. 1996, 39, 4149-4155.
57. (d) Avery, M. A.; Bonk, J. D.; Chong, W. K. M.; Mehrotra, S.; Miller, R. ; Milhous, W.; Goins, D. K.; Venkatesan, S.; Wyandt, C.; Khan, I.; Avery, B. A. Structure-activity relationships of the antimalarial agent artemisinin. 2. Effect of heteroatom substitution at O-11: Synthesis and bioassay of N-alkyl-11-aza-9-desmethylartemisinins. J. Med. Chem. 1995, 38, 26, 5038-44.
58. (e) Avery, M. A.; Chong, W. K. M.; Detre, G. Synthesis of (+)-8a,9-secoartemisinin and related analogues. Tetrahedron Lett. 1990, 31, 13, 1799-802.
59. (f) Avery, M. A.; Fan, P.; Karle, Jean, M.; Miller, R.; Goins, K. Replacement of the nonperoxidic trioxane oxygen atom of artemisinin by carbon: Total synthesis of (+)-13-carbaartemisinin and related structures. Tetrahedron Lett, 1995, 36, 23, 3965-8.
60. (g) Avery, M. A.; Chong, W. K. M.; Bupp, J. E. Tricyclic analogue of artemisinin: Synthesis and antimalarial activity of (+)-4,5-secoartemisinin and (-)-5-nor-4,5-secoartemisinin. J. Chem. Soc. Chem. Commun. 1990, 21, 1487-9.
61. (h) Avery, M. A.; Chong, W. K. M.; Bupp, J. Preparation of antimalarial analogues of artemisinin. WO 9114689 A1 19911003, 1991. Chem. Abstr. 117, 48951.
62. Makler, M. T.; Ries, J. M.; Williams, J. A.; Bancroft, J. E.; Piper, R. C.; Gibbins, B. L.; Hinriches, D. J. Parasite lactate dehydrogenase as an assay for Plasmodium falciparum drug sensitivity. Am. J. Trop. Med. Hyg. 1993, 48, 739-741.
63. (a) Sereno, D.; Roy, G.; Lemesre, J. L.; Papadopoulou, B.; Ouellette, M. DNA transformation of Leishmania infantum axenic amastigotes and their use in drug screening. Antimicrob. Agents Chemother. 2001, 45, 1168-1173.
64. (b) Babich, H.; Borenfreund, E. Cytotoxicity of T2 toxin and its metabolites with the neutral red cell viability assay. App. Envt Microbiol. 1991, 57, 2101-2103.
65. Lisgarten, J. N.; Potter, B. S.; Bantuzeko, C.; Palmer, R. A. Structure, absolute configuration, and conformation of the antimalarial compound, artemisinin. J. Chem. Crystallogr. 1998, 28, 539-543.
66. SYBYL 6.9, Force Field manual; Tripos Inc.: St Louis, MO, p 57.
67. Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital electronegativity: A rapid access to atomic charges. Tetrahedron 1980, 36, 3219-3222.
68. Stewart, J. J. P. MOPAC 6.0: A general molecular orbital package (QCPE 455); Frank J. Seiler Research Laboratory: Colorado Springs, CO.
69. Bush, B. L.; Nachbar, R. B., Jr. Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA. J. Comput-Aided Mol. Des. 1993, 7, 587-619.
70. 2-guided region selection for comparative molecular field analysis: A simple method to achieve consistent results. J. Med. Chem, 1995, 38, 1060-1066.
71. 2 guided region selection for CoMFA studies. In 3D QSAR methodology: CoMFA and related approaches; Kubinyi, H., Folkers, G., Martin, Y. C., Eds.; Kluwer Academic Publishers: Dordrecht, The Netherlands, 1998; Vol. III, pp 57-69.
72. Cramer, R. D., III; Bunce, J. D.; Patterson, D. E. Crossvalidation, bootstrapping, and partial least squares Compared with multiple regression in conventional QSAR studies. Quant. Struct.-Act. Relat. 1988, 7, 18-25.
73. Woolfrey, J. R.; Avery, M. A.; Doweyko, A. M. Comparison of 3D quantitative structure-activity relationship models: Analysis of the in vitro antimalarial activity of 154 artemisinin analogues by hypothetical active-site lattice and comparative molecular field analysis. J. Comput-Aided. Mol. Des. 1998, 12, 165-181.
74. Cheng, F.; Shen, J.; Luo, X.; Zhu, W.; Gu, J.; Ji, R.; Jiang, H.; Chen, K. Molecular docking and 3-D QSAR studies on the possible antimalarial mechanism of artemisinin analogues. Bioorg. Med. Chem. 2002, 10, 2883-2891.
75. Pal, J. K.; Purandare, M. J. Dose-dependent differential effect of hemin on protein synthesis and cell proliferation in Leishmania donovani promastigots cultures in vitro. J. Biosci. (Indian Acad. Sci.) 2001, 26, 225-231.